MedTrace Logo

Sevoflurane Sedation in Patients With Septic Shock

NCT03643367 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2025-04-01

No results posted yet for this study

Summary

Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.

Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

Conditions

  • Shock, Septic

Interventions

DRUG

Sevoflurane

Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.

DRUG

Control Group

Included patients randomized in control group, intravenouse sedation is continued with propofol

Sponsors & Collaborators

  • Kantonsspital Münsterlingen

    collaborator OTHER

  • Triemli Hospital

    collaborator OTHER

  • Waid City Hospital, Zurich

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Martin Schlaepfer, PD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2027-02-28
Completion
2027-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03643367 on ClinicalTrials.gov